Magnetic Seizure Therapy (MST) for Severe Mood Disorder

Condition(s) targeted: Major Depression

Intervention: Thymatron (Device); Magstim Theta (Device)

Phase: Phase 3

Status: Recruiting

Sponsored by: New York State Psychiatric Institute

Official(s) and/or principal investigator(s):
Sarah H. Lisanby, MD, Principal Investigator, Affiliation: New York State Psychiatric Institute

Overall contact:
Clinic Coordinator, Phone: (212) 543-5767, Email: depression@columbia.edu

This study will compare the clinical efficacy and side effects of Magnetic Seizure Therapy (MST) and Electroconvulsive Therapy (ECT) in patients currently experiencing a major depressive episode in the context of either unipolar or bipolar depression. The investigators will conduct a number of clinical and neuropsychological tests to assess clinical and cognitive response to treatment. The investigators hypothesize that:

1. MST and ECT will have similar antidepressant efficacy

2. MST will have less post-treatment amnesia than ECT as reflected in primary measures of anterograde and retrograde amnesia following the acute treatment phase.

3. At follow up, MST will show a lesser degree of persisting deficit in measures of retrograde amnesia than ECT.

Official title: Magnetic Seizure Therapy (MST) for the Treatment of Severe Mood Disorder

Study design: Treatment, Randomized, Double Blind (Subject, Outcomes Assessor), Active Control, Parallel Assignment, Efficacy Study

Primary outcome: Clinical improvement (Hamilton Rating Scale for Depression)

Secondary outcome: Clinical improvement (Inventory of Depressive Symptomatology - Clinician-Rated)

Detailed description: The purpose of this study is to compare the clinical efficacy and side effects of Magnetic Seizure Therapy (MST) and Electroconvulsive Therapy (ECT) in patients currently experiencing a major depressive episode in the context of either unipolar or bipolar depression. ECT is known to be highly effective in treating depression, but it can have some adverse cognitive side effects. MST is a new form of convulsive therapy that is being developed as a means of improving the side effect profile of ECT so that more patients may benefit without suffering significant detrimental effects on cognition.

Both ECT and MST cause a seizure, but they do so in different ways. In ECT, an electrical stimulator is used to pass an electrical current between two electrodes placed on the person's head, which causes some electricity to go through the brain and cause a seizure. In MST, a magnetic stimulator is used to pass a magnetic field to the brain, which then creates a small electrical field in the brain that causes a seizure.

In addition to the treatment sessions, this study will involve a number of assessments at different timepoints that are used to evaluate the person's antidepressant response and the physical and cognitive side effects of treatment.

Minimum age: 18 Years. Maximum age: 90 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Age 18-90

- Clinical diagnosis of major depressive episode, in the context of unipolar or bipolar

disorder

- Use of effective method of birth control for women of child-bearing capacity

- Willing and capable to provide informed consent

- Convulsive therapy clinically indicated

- Hamilton Rating Scale for Depression (HRSD24)≥ 20

Exclusion Criteria:

- Current unstable or serious medical condition, or any comorbid medical condition that

substantially increases the risks of ECT (such as acute myocardial infarction, space occupying brain lesion or other cause of increased intracranial pressure, unstable aneurysm or vascular malformation, poorly controlled diabetes mellitus, carcinoma, renal failure, hepatic failure)

- Pregnancy

- History of neurological disorder, epilepsy, stroke, brain surgery, metal in the head,

history of known structural brain lesion

- Presence of devices that may be affected by MST (pacemaker, medication pump, cochlear

implant, implanted brain stimulator)

- Breast-feeding

- History of head trauma with loss of consciousness for greater than 5 minutes

- History of schizophrenia, schizoaffective disorder, or rapid cycling bipolar disorder

- Vagus Nerve Stimulator implanted

- History of substance abuse or dependence in past 3 months

- Failure to respond to an adequate course of ECT in the current depressive episode

- History of ECT in the past 6 months and/or failure to respond to an adequate trial of

ECT lifetime

- Presence of intracardiac lines

Clinic Coordinator, Phone: (212) 543-5767, Email: depression@columbia.edu

New York State Psychiatric Institute, New York, New York 10032, United States; Recruiting
Clinic Coordinator, Phone: 212-543-5767, Email: depression@columbia.edu
Sarah H. Lisanby, M.D., Principal Investigator

University of Texas Southwestern Medical Center, Dallas, Texas 75390, United States; Not yet recruiting
Shawn McClintock, Ph.D., Phone: 214-648-2840
Mustafa M Husain, M.D., Principal Investigator

National Institute of Mental Health - Depression

Summary of MST on the Brain Stimulation Division web site

Related publications:

Lisanby SH, Luber B, Schlaepfer TE, Sackeim HA. Safety and feasibility of magnetic seizure therapy (MST) in major depression: randomized within-subject comparison with electroconvulsive therapy. Neuropsychopharmacology. 2003 Oct;28(10):1852-65.

Kosel M, Frick C, Lisanby SH, Fisch HU, Schlaepfer TE. Magnetic seizure therapy improves mood in refractory major depression. Neuropsychopharmacology. 2003 Nov;28(11):2045-8.

Starting date: June 2007
Ending date: June 2012
Last updated: September 8, 2008